Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

(Photo: Mike Kemp/In Pictures via Getty Images)

Several states are considering new "affordability boards" to rein in prescription drug prices. They're hoping that approach would avoid the legal pitfalls that tripped up earlier state-based policies.

How it works: These new boards would review expensive drugs and, if it deems them too expensive, set a new, lower price that insurance plans would have to pay.

Details: Several states have introduced bills following a model by the National Academy for State Health Policy:

  • The new affordability boards would review drugs with high launch prices (above $30,000) or big price increases (more than 10% or $10,000 in a year). For generics, the threshold would be launch prices above $3,000 or price increases exceeding 25% or $300.
  • If a state's board determines that a drug isn't affordable for the state, it can set a payment rate that insurers must abide by.
  • “It’s setting the force of law behind what the payer will pay, and requiring the supply chain to work it out, which they always do," said Jane Horvath, a health care consultant working with states on the bills.

Where it stands: Maryland's bill has the most momentum so far, and the effort is partially a response to the defeat of the state's proposal to counter "price gouging," which was knocked down in court.

  • Proponents say regulating payers, not the actual drug prices, puts them on safer legal ground.
  • “If a state can't do this, there’s nothing else they can do, other than importation," Horvath said.

The other side: Opponents say they'll make some of the same legal arguments that sank Maryland's earlier proposal.

  • "States that attempt to regulate transactions outside of their own borders will face constitutional scrutiny," said Jeff Francer, general counsel of the Association for Accessible Medicines, which represents generics manufacturers and joined the lawsuit against Maryland's price-gouging bill.
  • "Letting the government set prices for medicines is merely a retread of failed policies and political talking points that won’t address the affordability challenges patients are facing and could potentially limit their access to the medicines they need," the Pharmaceutical Research and Manufacturers of America said in a statement.

Go deeper

Cuomo: "No way I resign" after sexual harassment accusations

Cuomo at a Feb. 24 press conference. Photo: Seth Wenig/pool/AFP via Getty Images

New York Gov. Andrew Cuomo (D) was defiant on Sunday, stating again that he would not resign even as more former aides have come forward with allegations of sexual harassment and inappropriate behavior.

The big picture: Cuomo has denied all sexual harassment allegations against him and said that he "never inappropriately touched anybody." He acknowledged in a statement that "some of the things I have said have been misinterpreted as an unwanted flirtation." Some of the calls for Cuomo to resign have come from within the Democratic party.

N.Y. Times faces culture clashes as business booms

Illustration: Sarah Grillo/Axios

New York Times columnist David Brooks' resignation from a paid gig at a think tank on Saturday is the latest in a flurry of scandals that America's biggest and most successful newspaper company has endured in the past year.

Driving the news: Brooks resigned from the Aspen Institute following a BuzzFeed News investigation that uncovered conflicts of interest between his reporting and money he accepted from corporate donors for a project called "Weave" that he worked on at the nonprofit.

America rebalances its post-Trump news diet

Illustration: Annelise Capossela/Axios

Nearly halfway through President Biden's first 100 days, data shows that Americans are learning to wean themselves off of news — and especially politics.

Why it matters: The departure of former President Trump's once-ubiquitous presence in the news cycle has reoriented the country's attention.